Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SHSE:688336's Cyclically Adjusted PS Ratio is ranked worse than 86.94% of 536
companies
in the Biotechnology industry
Industry Median: 5.725
vs SHSE:688336: 31.96
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Sunshine Guojian Pharmaceutical (Shanghai) Co's adjusted revenue per share data for the three months ended in Mar. 2026 was ¥0.484. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is ¥1.51 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Sunshine Guojian Pharmaceutical (Shanghai) Co Cyclically Adjusted PS Ratio Related Terms
Sunshine Guojian Pharmaceutical (Shanghai) Co Cyclically Adjusted PS Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sunshine Guojian Pharmaceutical (Shanghai) Co Cyclically Adjusted PS Ratio Chart
Sunshine Guojian Pharmaceutical (Shanghai) Co Annual Data
SHSE:688336 vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Sunshine Guojian Pharmaceutical (Shanghai) Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sunshine Guojian Pharmaceutical (Shanghai) Co Cyclically Adjusted PS Ratio vs Biotechnology Industry
Sunshine Guojian Pharmaceutical (Shanghai) Co Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 32.05 mean?
Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) has a Cyclically Adjusted PS Ratio of 32.05 as of Aug. 14, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. This is 92% above median its historical median of 16.73. Over the past decade, Sunshine Guojian Pharmaceutical (Shanghai) Co's Cyclically Adjusted PS Ratio has ranged from 10.50 to 48.47. According to the industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #466 out of 536 companies in the Biotechnology industry, placing it in the top 86.9%.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co's Cyclically Adjusted PS Ratio too high?
Sunshine Guojian Pharmaceutical (Shanghai) Co's current Cyclically Adjusted PS Ratio of 32.05 is 92% above median its 10-year median of 16.73. Over the past 10 years, this metric has ranged from a low of 10.50 to a high of 48.47. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.73. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 32.05 is 459.8% above this industry median. Based on the distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #466 out of 536 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Sunshine Guojian Pharmaceutical (Shanghai) Co has a GF Score™ of 80/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sunshine Guojian Pharmaceutical (Shanghai) Co's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Sunshine Guojian Pharmaceutical (Shanghai) Co ranks #466 out of 536 companies for Cyclically Adjusted PS Ratio. This places Sunshine Guojian Pharmaceutical (Shanghai) Co in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.73. Sunshine Guojian Pharmaceutical (Shanghai) Co's value of 32.05 is 459.8% above this benchmark. Historically, Sunshine Guojian Pharmaceutical (Shanghai) Co's own Cyclically Adjusted PS Ratio has ranged from 10.50 to 48.47 over the past decade. While the company's 10-year median is 16.73 vs. the industry median of 5.73, Sunshine Guojian Pharmaceutical (Shanghai) Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.73, based on 536 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Cyclically Adjusted PS Ratio of 32.05 is 459.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Sunshine Guojian Pharmaceutical (Shanghai) Co and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.73 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sunshine Guojian Pharmaceutical (Shanghai) Co's current Cyclically Adjusted PS Ratio is 32.05, which is 92% above median its own 10-year median of 16.73. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co stock overvalued right now?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥68.02, compared to a current price of ¥48.40 — trading 28.8% below its estimated fair value. The current Cyclically Adjusted PS Ratio is 32.05, which is 92% above median its 10-year median of 16.73 and 459.8% above the Biotechnology industry median of 5.73. Sunshine Guojian Pharmaceutical (Shanghai) Co's overall GF Score™ is 80/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336), the current Cyclically Adjusted PS Ratio is 32.05 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sunshine Guojian Pharmaceutical (Shanghai) Co (SHSE:688336) Overvalued in 2026?
Based on GuruFocus' analysis, Sunshine Guojian Pharmaceutical (Shanghai) Co stock appears to be undervalued.
The current stock price of ¥48.40 is trading 28.8% below its estimated GF Value™ of ¥68.02.
GuruFocus considers Sunshine Guojian Pharmaceutical (Shanghai) Co to be Modestly Undervalued.
Key valuation signals for SHSE:688336:
Cyclically Adjusted PS Ratio: 32.05 (92% above median its 10-year median of 16.73)
GF Value™: ¥68.02 vs. price of ¥48.40 (28.8% below fair value)
Industry Position: 459.8% above the Biotechnology median (#466 of 536)
No single metric tells the full story. See the SHSE:688336 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sunshine Guojian Pharmaceutical (Shanghai) Co Ltd is a biopharmaceutical company providing safe and effective clinical solutions for the treatment of major diseases such as autoimmune diseases and tumors. The company engages in in research and development, manufacturing and commercialization of therapeutic antibody drugs in China. Its products portfolio includes YISAIPU and Xenopax. Its products in pipeline include 302H, 304R, 602, 601A, 609A and 301S.
80GF Score
Get the complete analysis for SHSE:688336
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688336 has been successfully added to your 
